My Profile

Search abstracts

Lewis Sheiner


2017
Budapest, Hungary



2016
Lisboa, Portugal

2015
Hersonissos, Crete, Greece

2014
Alicante, Spain

2013
Glasgow, Scotland

2012
Venice, Italy

2011
Athens, Greece

2010
Berlin, Germany

2009
St. Petersburg, Russia

2008
Marseille, France

2007
København, Denmark

2006
Brugge/Bruges, Belgium
   Program
   Organisers
   Abstracts
   Participants

2005
Pamplona, Spain

2004
Uppsala, Sweden

2003
Verona, Italy

2002
Paris, France

2001
Basel, Switzerland

2000
Salamanca, Spain

1999
Saintes, France

1998
Wuppertal, Germany

1997
Glasgow, Scotland

1996
Sandwich, UK

1995
Frankfurt, Germany

1994
Greenford, UK

1993
Paris, France

1992
Basel, Switzerland


2006
   Brugge/Bruges, Belgium


Al Za’abi MA (1), Xiaonian X (2), Donovan T (3), Charles BG (1)
Use of Routine Data for Determination of the Population Pharmacokinetics and Enteral Bioavailability of Phenytoin in Neonates and Infants with Seizures
Bertrand, Julie, Emmanuelle Comets, France Mentré
Detecting a gene effect in pharmacokinetic models: comparison of different methods
Bogacka, Barbara (1) Maciej Patan (2)
Efficient Sampling Windows for Parameter Estimation in Population Models
Boström, Emma, Ulrika S. H. Simonsson and Margareta Hammarlund-Udenaes
In vivo blood-brain barrier transport of oxycodone in the rat – active influx and implications for PK/PD
Brendel, Karl(1,3), Céline Dartois(2,3), Emmanuelle Comets(1), Christian Laveille(4), Annabelle Lemmenuel-Diot(3), Brigitte Tranchand(2,6), Pascal Girard(2,5), Céline Laffont(3), France Mentré(1)
Are population PK/PD models adequately evaluated? An exhaustive survey of the literature between 2002 and 2004
Prins, K (1), B. Poland (1), V. Nicolas (2), H. Porchet (2), P. Scalfaro (2), R. Bruno (1)
Modeling and Simulation of DEBIO-025 to Support Design of a Dose-Response Monotherapy Study in HIV-1 infected Patients
Claret, L. (1), P. Girard (2), K.P. Zuideveld(3), K. Jorga (3), J. Fagerberg (3), R. Bruno (1)
A longitudinal model for tumor size measurements in clinical oncology studies
Gaynor, Clare (1), Dunne, Adrian (1) and Davis, John (2)
Comparison of conventional In Vitro - In Vivo Correlation methodology with non-linear mixed effects modelling
Bulitta, J.(1), T. P. Lodise(2), G. L. Drusano(3), M. Kinzig-Schippers(1), U. Holzgrabe(4), F. Sörgel(1,5)
Bias and Uncertainty of Monte Carlo Simulations with Beta-Lactams
Carlsson, Kristin C., Radojka M. Savic, Andrew Hooker, Mats O. Karlsson.
Mixture models in NONMEM - how to find the individual probability of belonging to a specific mixture, and why this can be useful information
Chantel, S.(1,2), P. Martin(1,2), P.Y. Petit (3), D. Massignon(4), X. Dode(1), P. Maire (5), R.W. Jelliffe(6), G. Aulagner(1,2)
Pharmacokinetic variability of the absorption of enoxaparin used subcutaneously for venous thromboembolism prophylaxis
Nekka, Fahima (1,2), Caroline-E. Petit-jetté (1), Jun Li (1,2), Denis Gohore Bi (1), Renée Bergeron (3), Jérome del Castillo (4)
Therapeutic modelling and analysis of random feeding features of feed-administered chlortetracycline
Armendariz Y2, Caldes A2 , Colom H1, Gilvernet S2, Peraire C1, Domenech J1, Grinyó JM2, Wilkins J3, Karlsson M3.
Population pharmacokinetics of Valganciclovir in solid organ transplant recipients infected by cytomegalovirus
Comets, Emmanuelle(1) and Céline Verstuyft (2)
Analysis of digoxin data using Non-Parametric Maximum Likelihood (NPML)
Cronier, D. (1,5), E. Grenier (2), M. Lecomte (3), V. Autier (3), B. Ladstetter (4), L. J. Aarons (5), and J.P. Boissel (1)
Modelling of insulin secretion: from beta-cell physiology to sulphonylurea-mediated insulin secretion
Dansirikul, C. H.E. Silber, M.O. Karlsson
Comparison of models for baseline
Dartois, C (1)(4), K Brendel (2)(4), E Comets (2), C Laveille (3), C Laffont (4), B Tranchand (1)(5), F Mentré (2), A Lemenuel-Diot (4), and P Girard (1)(6).
How is model building reported for population PK-PD? An exhaustive survey of the literature between 2002 and 2004
Dehez, Marion(1)(2)(3), Marylore Chenel(1), Roeline Jochemsen(1), Stéphanie Ragot(2)
Population modeling approach of circadian blood pressure variations using ambulatory monitoring in dippers and non dippers
GastroPlus
GastroPlus
Dodds, M.G. (1), J.E. Visich(1), I. Nestorov(1), R. Overgaard(2), M.C. Rogge(1)
Population pharmacodynamic model of the effects of recombinant human interleukin 21 on platelets in humans
Dokoumetzidis, Aris and Leon Aarons
Direct application of Bayes theorem for the combination of population pharmacokinetic analyses.
Duffull, S B (1), G Graham (2), K Mengersen (3)
Bayesian Estimation of Optimal Sampling Times for Pharmacokinetic Models
Edginton, A.N.(1), S. Willmann (1), Sevestre, M (2), Kirchheiner, J (3)
Determining the effect of CYP2C9 genotypes on diclofenac metabolism using individualized coupled physiology-based pharmacokinetic modeling
Edginton, A.N. (1), S. Willmann (1), M. Kleine-Besten (2)
Use of a physiology-based whole-body population model to simulate the influence of anthropometric-, clearance-, and physiological-variance on the pharmacokinetics of drugs
Elsherbiny, D.(1), S. Asimus(2), M.O. Karlsson(1), M. Ashton(2), U. S. H. Simonsson(1)
Modeling of the induction of CYP2B6 and CYP2C19 by artemisinin antimalarials
ICON Development SolutionsTM
Hands-On Demonstration of PDx-Pop® v2.0; Tools for Expediting Population Analysis
Friberg, Lena E.(1), An M. Vermeulen(2), Mats O. Karlsson(1)
A mechanism-based pharmacokinetic-pharmacodynamic model of the time-course of prolactin following antipsychotic drug treatment
Gibiansky, Ekaterina (1), Leonid Gibiansky (2)
Model-Based Drug Development: Optimization of AQUAVAN® Injection Dosing for Minimal-to-Moderate Sedation
Gibiansky, Leonid, Marc R. Gastonguay
R/NONMEM Toolbox for Simulation from Posterior Parameter (Uncertainty) Distributions
Grasela, Thaddeus(1), Jill Fiedler-Kelly(1), Cynthia Walawander(1), Charles W. Dement(2)
Challenges in the Transition to Model-Based Development
Gupta, M, K Wade, B Jayaraman, J Mondick, JS Barrett
Optimizing Fluconazole Dosing in Preterm Neonates Based on Simulations from Posterior Parameter (Uncertainty) Distributions
Guzy, Serge
Monte Carlo Parametric Expectation Maximization (MC-PEM) Method for Analyzing Population Pharmacokinetic/ Pharmacodynamic (PK/PD) Data
Guzy, Serge
The PDX-MC-PEM software
Hempel, Georg; Lanvers-Kaminsky, Claudia; Ahlke, Elvira; Müller, Hans-J.; Würthwein, Gudrun; Boos, Joachim
A Population Model Describing the Activity-time Course of Pegylated Asparaginase in Children
Hénin, Emilie(1), Klaas P. Zuideveld (2), Céline Dartois (1), Brigitte Tranchand (1,3), Gilles Freyer (1,4), Pascal Girard (1,5)
A KPD Model for ordered categorical data: application to toxicity score in colorectal cancer patients treated with capecitabine
Hennig, S. (1,2), Wainwright, CE. (3), Bell, SC. (4), Miller, H. (2) Friberg, LE. (1) and Charles, BG. (1)
Paediatric population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in cystic fibrosis and bone marrow transplant patients
Hennig, S. (1,2), Waterhouse T.(1) Wainwright C.(3), Bell S.(4), Miller H. (2), Charles B.(1) and Duffull S.(1)
A D-optimal designed population pharmacokinetic study of itraconazole capsules and solution in adults with cystic fibrosis
Hing, Jeremy(1), Juan Jose Perez-Ruixo(1), Kim Stuyckens(1), Peter Zannikos(1), Arturo Soto-Matos(2), César Picó(2), Antoine Yver(1) and Andrew Chow(1)
Population PK/PD Modelling & Simulation of Hematological Toxicity of Trabectedin in Cancer Subjects
Holford, Nick, Carl Kirkpatrick, Steve Duffull
NONMEM Termination Status is Not an Important Indicator of the Quality of Bootstrap Parameter Estimates
Hooker, Andrew, Christine E. Staatz and Mats O. Karlsson.
Conditional weighted residuals, an improved model diagnostic for the FO/FOCE methods.
Hutmacher, Matthew M , Anand Vidyashankar, and Debu Mukherjee
Model Selection Using the Minimum Hellinger Distance Criterion (MHDC) with an Introduction to Minimum Hellinger Distance Estimation (MHDE)
Hutmacher, Matthew M, Sriram Krishnaswami
An extension of the indirect response models to ordered categorical pharmacodynamic data using latent variables
Jelliffe, R., A Schumitzky, D Bayard, R Leary, M Van Guilder, A Gandhi, M Neely, and A Bustad.
The USC*PACK BigWinPops and MM-USCPACK Software
Joerger, M., A.D.R. Huitema, V. D. Doodeman, H. Boot, R. W. Sparidans, J.H. Beijnen, J.H.M. Schellens
Epirubicin pharmacokinetics-pharmacodynamics and metabolic pathway-associated gene polymorphisms: Significant influence of the novel UDP-glucuronosyltransferase 2B7 promoter mutation -66T>C
Karlsson, Mats O. and Radojka Savić
Overview of oral absorption models and modelling issues
Hamrén, Bengt(1), Elisabeth Björk (1), Mats O. Karlsson (2)
Mechanism-based pharmacokinetic and pharmacodynamic modelling of tesaglitazar in type 2 diabetes patients
Kowalski, Kenneth G., Stephen Olson, Ann Remmers
A Modeling and Simulation Case Study: Impact on an Early Clinical Development Program
Kuester, K(1), A. Kovar(2), B. Brockhaus(2), C. Kloft(1,3)
Population Pharmacokinetic Analysis for Matuzumab (EMD 72000) – A Humanised EGFR-Targeted Monoclonal Antibody
Landersdorfer, C.(1), C. M. J. Kirkpatrick(2), M. Kinzig-Schippers(1), J. Bulitta(1), U. Holzgrabe(3), F. Sörgel(1,4)
New Insights into the Most Commonly Studied Drug Interaction with Antibiotics: Pharmacokinetic Interaction between Ciprofloxacin, Gemifloxacin and Probenecid at Renal and Non-renal Sites
Langdon G (1), Gueorguieva I (2), Aarons L (3), Karlsson MO (1)
Linking preclinical and clinical whole body physiologically-based pharmacokinetic models with prior distributions in NONMEM
Lavielle, Marc (1,2,3) Hector Mesa (1) Julie Bertand (4) Adeline Samson (4) France Mentré (4) and the Monolix group
Analysing population PK/PD data with the MONOLIX software
Leary, Robert H. and Dunlavey, Michael
Parallel Processing for Nonlinear Mixed Effects Modeling
Lehr, T. (1), A. Staab (2), C. Tillmann (2), D. Trommeshauser (2), A. Raschig (2), H.G. Schaefer (2), C. Kloft (1,3)
Efficacy modelling of NS2330 in mild Alzheimer’s disease patients
Lehr, T.(1), A. Staab (2), C. Tillmann (2), D.Trommeshauser (2), A. Raschig(2), H.G. Schaefer (2), C. Kloft (1,3)
Population pharmacokinetics of NS2330 and its major metabolite in Alzheimer’s disease patients
Zeumer, D., A. Staab, T. Lehr, C. Tillmann, K.-H. Liesenfeld, H. G. Schaefer
PROPHET - A convenient and efficient environment for the use of NONMEM in a global pharmaceutical company
Lindbom, Lars(1), Justin J Wilkins(1), Nicolas Frey(2), Mats O Karlsson(1), E Niclas Jonsson(1,2)
Evaluating the evaluations: resampling methods for determining model appropriateness in pharmacometric data analysis
Lopez-Pintor E (1), Valenzuela B (1), Montesinos A (2), Martín-Villodre A (2), Casabó V.G (2)
Population pharmacokinetics approach for salbutamol sulphate in rats
Lovern, Mark R , Ginny Schmith, George Dukes, David McSorley
Using a Placebo Response Model to Optimize Clinical Trial Designs for Irritable Bowel Syndrome (IBS) Therapies
Marshall, Scott1, Mike K Smith1, Eugene Cox2,3 and Jaap Mandema2,4
Application of PK/PD modelling in the development eletriptan DR for the treatment of acute migraine and prevention of headache recurrence.
Matthews, Ivan (1), Smith, Fang Gao (2), Aarons, Leon (1)
Pharmacokinetics of a single bolus of propofol in Chinese children of different ages
Matthews, Ivan and Aarons, Leon
A population pharmacokinetic model for s-warfarin: application of a mixture model to determine genotype/phenotype.
Miller, Raymond , Howard Bockbrader, Sunny Chapel.
Comparision of Pregabalin and Gabapentin Pharmacodynamics in Patients with Refractory Partial Seizures.
Mills, Richard (1,2), Kayode Ogungbenro (1) & Leon Aarons (1)
Simultaneous fitting of the Minimal Model to IVGTT and Glucose Clamp Data
Mondick, John T.(1), Leonid Gibiansky (2), Marc R. Gastonguay (2), Gareth J. Veal (3), Jeffrey S. Barrett (1)
Acknowledging Parameter Uncertainty in the Simulation-Based Design of an Actinomycin-D Pharmacokinetic Study in Pediatric Patients with Wilms’ Tumor or Rhabdomyosarcoma
Plock, N.(1), C. Buerger(1), K. Kuester(1), C. Joukhadar(2), S. Kljucar(3), C. Kloft(1,4)
A Population Pharmacokinetic Model for the Simultaneous Description of Linezolid Tissue and Plasma Disposition in Healthy Volunteers and Septic Patients
Nalda-Molina, R (1), Bermejo M. (2), Casabó V.G. (2)
A simple physiological-pharmacokinetic model to simulate bioequivalence trials
Fernández-Teruel C, Navarro-Fontestad MC, González-Álvarez I, Bermejo M, Casabo VG
Sparse sampling designs: a new method for estimating the complete AUC and its standard error
Nestorov, I.1, A. Munafo2, O. Papasouliotis2, J. Visich1 and M. Rogge1
Population modeling of the relationship between TACI Ig exposure and biomarker response in patients with rheumatoid arthritis (RA)
Nielsen, Elisabet I(1), Uwe Ewald (2), Lena E Friberg (1)
Population Pharmacokinetics of Gentamicin in Preterm and Term Newborn Infants
Olofsen, E.
Using the Lasso to simultaneously identify the covariate and variance-covariance structures of nonlinear mixed-effects models
Ortega, Ignacio , An Vermeulen, Vladimir Piotrovsky
Concentration-response analysis of antipsychotic drug effects using an indirect response model
Paccaly, A (1), Speth, H (2), Jensen, BK (1), Maas, J (2)
Non-Linear Population Pharmacokinetic Model for Otamixaban in Healthy Male Subjects
Panhard, Xavière and Adeline Samson
Extension of the SAEM algorithm for the estimation of Inter-Occasion Variability: application to the population pharmacokinetics of nelfinavir and its metabolite M8
Perez Ruixo, Juan Jose
Optimizing the Design of Phase I Studies of Erythropoietin Receptor Agonist Through Mechanism-Based PK/PD Modeling and Simulation
Marchand, M. (1), O. Petricoul (1), E. Fuseau (1), D. Bentley (2), D. Critchley (2)
Extrapolation from preclinical PKPD data to clinical response, Application to a new antiepileptic medication (drug X)
Pihlgren, Pontus, Lars Lindbom, Niclas Jonsson
Transforming a set of office computers to a computing cluster.
Post, T.M.(1), J.I. Freijer (1), W. de Winter (1), B.A. Ploeger (1,2)
Accurate Interpretation of the Visual Predictive Check in order to Evaluate Model Performance
Mango Solutions
Mango Solutions
Quartino, Angelica L., Lena E. Friberg, Mats O. Karlsson
A simultaneous analysis of the time course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic model
Ramón-López A. (1), Nalda-Molina R. (1), Valenzuela B. (1), Pérez Ruixo J.J.(1), Jiménez Torres N.V.(2),
Semi-mechanistic KPD model for haematological toxicity in breast cancer patients receiving high dose of chemotherapy
Renard, D.(1b), J. Witcher (1a), Y. Nie (2), F. Vandenhende (1b), A. Kumar (3), J. Miller (1a), J. Tauscher (1a), Y. Zhou (3), D. Wong (3)
Bayesian Hierarchical Modeling of Receptor Occupancy in PET Trials
Dittberner, S.(1), V. Duval (2), A. Staab (2), H. Fuchs (2), M. Tadayyon (2), U. Graefe-Mody (2), H.G. Schaefer (2), U. Jaehde (1)
Pre-Clinical PK/PD Modeling for a Dipeptidyl Peptidase-IV Inhibitor
Retout, Sylvie, Emmanuelle Comets, Hervé Le Nagard and France Mentré
New features for population designs evaluation and optimisation in R: PFIM 2.0 and PFIMOPT 2.0
Ribbing, J. (1), J. Nyberg (1), O. Caster (1), E.N. Jonsson (1,2)
The LASSO - A Novel Method for Predictive Covariate Model Building in Nonlinear Mixed Effects Models
Rodrigues, C.L. (1) , I. Gueorguieva (2), Marylore Chenel (3), D. A. Berk (4) and L. Aarons (1)
Norfloxacin – a whole body physiologically based pharmacokinetic model
Rostami-Hodjegan, A.
Complications in assessing the hepatic first-pass component of bioavailability
Prémaud, A(1), Van Guilder M (2), Armstrong VW (3), Weber LT(3), Ghandi A (2), Oellerich M (3), Tonshoff B (3), Jelliffe R (2), Marquet P (1), Rousseau A (1)
Population pharmacokinetics and Bayesian estimation of mycophenolate mofetil in paediatric renal transplant recipients using a non-parametric approach.
Djebli, Nassim 1, Pierre Marquet1,2, Yann Le Meur1,3, Annick Rousseau1,4
Population pharmacokinetics of sirolimus in adult renal transplant patients and Bayesian estimation of individual systemic exposure
Rostami-Hodjegan A, Rowland-Yeo K, Jamei M
Simcyp - a platform for simulation and prediction of in vivo drug disposition in virtual human populations
Roy, A. and M. Pfister
Optimizing Dose Selection With Respect to Multiple Safety/Efficacy Endpoints Using Clinical Utility Concepts
Roy Pierre, Annabelle Lemenuel-Diot, Marylore Chenel
Is it possible to perform equivalent simulations with NONMEM and TS2?
Samson, Adeline (1), Marc Lavielle (2) and France Mentré (1)
The SAEM algorithm for non-linear mixed models with left-censored data and differential systems: application to the joint modeling of HIV viral load and CD4 dynamics under treatment
Hussein, Ziad(1), Brigitte Lacroix(2), Maria-Laura Sargentini-Maier(2)
Population pharmacokinetics of the new antiepileptic drug brivaracetam
Savic, Radojka M. , Maria C. Kjellsson, Mats O. Karlsson
Evaluation of the nonparametric estimation method in NONMEM VI beta
Silber, Hanna E., Maria C. Kjellsson and Mats O. Karlsson
The likelihood ratio test appears robust to most residual error model misspecifications
Holford, Nick, Goonaseelan (Colin) Pillai, Sandip Roy, Andrej Skerjanec, Serge Cremers, William Collins, Jean-Louis Steimer
Population pharmacokinetics of balicatib, a cathepsin K inhibitor
Holford, Nick, Goonaseelan (Colin) Pillai, Nitin Kaila, William Collins, Sandip Roy, Serge Cremers, Ulrich Trechsel, Florilene Bouisset, Jean-Louis Steimer
PKPD model for cathepsin K inhibition with balicatib and changes in bone turnover biomarkers, in particular NTx
Tajima, Takeshi(1), Akihiro Yokoi (1), Peiming Ma (2), Ryosei Kawai (1)
Population approach to assess the relationship of cyclosporin exposure and renal dysfunction in Japanese patients with rheumatoid arthritis
Testart, D.(1), G. Blanc(2), P. Delrat(1), T. Shepard(1)
Development of a tool to simulate intra-individual variability encountered in animals from standard preclinical toxicological study
Thomas, F.(1), S Séronie-Vivien(1), F Bouissou(2), M Tafani(2), JP Delord(1), L Gladieff(1), E Chatelut(1)
Cystatin C as a new covariate to predict the renal elimination of drugs
Tousset, E.(1), H. Figueiredo (2),M.P. Schneider(2),O. Bugnon(2), B.Vrijens (1)
Relation between patients’ variable compliance and office blood pressure in treatment-resistant hypertension.
Lindbom, L.(1), K. Tunblad(1), L. McFadyen(2), E.N. Jonsson(1), S. Marshall(2), M. O. Karlsson(1)
The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data
Valle M, Grasa E, Yritia M, Romero S,, Barbanoj MJ.
Population Pharmacokinetic-Pharmacodynamic modelling of olanzapine effects on the electroencephalogram in healthy volunteers.
van Eijkeren, J.C.H. (1), M.J. Zeilmaker (1), C.A. Kan (2), L.A.P. Hoogendoorn (3) and W.A. Traag (3)
Model building and model parameter identification for transfer of dioxin TEQs from feed to eggs.
van Hest, Reinier1, Teun van Gelder1,2, Arnold Vulto1, Leslie Shaw3, Ron Mathôt1
Pharmacokinetic modeling of plasma protein binding of mycophenolic acid in renal transplant recipients
Verbeke, Geert
Mixed models for the analysis of categorical repeated measures
Viberg, Anders (1), Otto Cars (2), Mats O. Karlsson (1) and Siv Jönsson (3)
Individualization of Cefuroxime Dosage using Pharmacodynamic targets, MIC distributions and Minimization of a Risk Function
Vicini, Paolo
The Population Approach Identity Crisis: The Search For Innovation In Modeling And Simulation
Vicini, Paolo and the Resource Facility for Population Kinetics (RFPK)
The System for Population Kinetics (SPK)
Barrett, Jeffrey S. PhD, FCP1, Kalpana Vijayakumar, MS2, Sriram Krishnaswami, PhD3, Manish Gupta, PhD1, John Mondick, PhD1, Bhuvana Jayaraman, BS1, Arun Muralidharan, BS1, Srinivas Santhanam, MS1 and S. Vijayakumar, PhD2
iClinical: NONMEM Workbench
Vis, Peter (1), Vanitha Sekar (2), Erno van Schaick (1) and Richard Hoetelmans (3)
Development and application of a population pharmacokinetic model of TMC114 in healthy volunteers and HIV-1 infected subjects after administration of TMC114 in combination with low dose ritonavir
Wallin, Johan E, Friberg Lena E., Karlsson Mats O.
An Adaptive Dosing Tool For Etoposide Using Neutrophil Counts Based on a Semi-Physiological Model
Weatherley B., L. McFadyen, P. Milligan
Population Analysis of Maraviroc Phase 1 Noncompartmental Pharmacokinetic Data
Wilkins, Justin J (1), Karlsson, Mats O (1), Jonsson, E Niclas (2)
Patterns and power for the visual predictive check
Wilkins, Justin J (1), Hooker, Andrew (1), Karlsson, Mats O (1), Jonsson, E Niclas (2)
Xpose – an R-based population pharmacokinetic/pharmacodynamic model-building aid for NONMEM
William Faltaos, D (1), S. Urien (1), V.Morel (2), G. Kaloshi (3), k. Hoang Xuan (3), V.Leblond (2), Philippe Lechat (1).
Population pharmacokinetic study of methotrexate in patient with lymphoid malignancy
Willmann, Stefan, Wolfgang Weiss, Andrea N. Edginton
Hands-On Demonstrations of the Physiology-Based Pharmacokinetic Software, PK-Sim®
Willmann, Stefan, Andrea N. Edginton, Walter Schmitt, Marcus Kleine-Besten, and Jennifer B. Dressman
Simulating Oral Absorption with PK-Sim®: Methodology and Application Examples
Woltosz, Walter S. and Michael B. Bolger
Simulation of the Nonlinear PK of Gabapentin and Midazolam in Adult and Pediatric Populations
Yim, Dong-Seok (1), Dong-Gun Lee, Su-Mi Choi, Wan-Shik Shin, Hyon-oh Lah(1)
Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea
Zandvliet, Anthe S.(1), Alwin D.R. Huitema (1), William Copalu (2), Yasuhide Yamada (3), Tomohide Tamura (3), Jos H. Beijnen (1,4) , Jan H.M. Schellens (4,5)
Pharmacogenetically guided dosing of the anticancer agent indisulam normalizes the risk of severe hematological toxicity
Zandvliet, Anthe S. (1), Wandena S. Siegel-Lakhai (1), Jan H.M. Schellens (2,3), William Copalu (4), Gerard Milano (5), Jos H. Beijnen (1,3), Alwin D.R. Huitema (1)
Semi-mechanistic PK/PD model of indisulam in combination with capecitabine: a time-dependent pharmacokinetic interaction contributes to excessive hematological toxicity